Drug intelligence / Profile preview

QCZ484

Development stage: Phase 2
Lead developer: Novartis
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

QCZ484 is an investigational RNA therapeutic developed by Novartis for the treatment of hypertension. It is administered as a subcutaneous injection every six months and is currently being evaluated in phase 2 clinical trials for efficacy, safety, and tolerability in patients with mild to moderate hypertension. The precise mechanism of action has not been disclosed publicly. The drug utilizes Novartis's xRNA technology platform[1][2][3][5].

Targets

AGT (O6-methylguanine-DNA methyltransferase)

Beyond the preview

Go deeper on QCZ484.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QCZ484.

Explore the full profile